About Us
Inheriting Scientific Innovation for Drug Development
Fidelity Regulation Therapeutics Inc., FRT, is a start-up clinical stage drug development company.
Founded in 2019, FRT consists of a professional team with consultant team from both research institutes and the industries, including small/large molecules drugs design, cell therapy and clinical trials professionals.
Founder Profile
Dr. Shiau is the founder, President and Chief Executive Officer of FRT. Prior to FRT, He served as an associate professor in National Defense Medical Center (NDMC). He devoted most of his life in research, 38 years and still counting. Not only did he establish academic connections and reputation from academic visiting globally, but also able to give constructive advice to the companies from the experience of being the Centre for Drug Evaluation consultant on CMC section in 2001-2003.
Dr. Shiau is a registered pharmacist. During his carrier life in NDMC, he served as a head of production unit, head of packing and delivery unit, manager of administrative unit, and R&D member of Medical Laboratory of NDMC for parental injection product production.
He was also a leader of a Pharmaceutical factory, in charge of producing various medicines including tablets, eye drop products, various kind of ampoules for injection, solutions for external use, and pharmaceutical raw materials for veterans and military.
Dr. Shiau has appeared as co-author or co-inventor on nearly 50 publications and patents. He received his Dphil. in Biochemistry, Centre for Molecular Sciences/ Dyson Perrins Laboratory in 1995 from the University of Oxford under Prof. Jack E. Baldwin and Dr. Chris J. Schofield. He returned as a postdoctoral fellow from 1997-1998.
Technology
scFv Human Antibody Library
FRT developed a scFv Human antibody library based on phage display technology. Through our platform and our expertise, we assist costumers in:
- New antibody drug development
- Specific monoclonal antibodies productions